parallax background

Supervisor Database Search

Search for supervisors below. You can filter your search using the options and select
multiple fields by holding CTRL (Cmd on Mac) + clicking multiple options in a list.

Full NameProfessor Richard Kennedy

Department:CENTRE FOR CANCER RESEARCH AND CELL BIOLOGY

Organisation:Queen's University Belfast

Webpage:qub.ac.uk

Email Address:Email hidden; Javascript is required.

Research Fields
  • genetics, genomics and molecular biology
  • cancer/oncology
  • Other
Other Research Fields:

Immune checkpoint PD-L1 cGAS STING "DNA Repair"

Postgrad Medical Specialties
  • Medicine
  • Pathology
Medical Subspecialties
  • Immunology
  • Oncology
  • Pharmacology
My Work

The Kennedy lab was the first to describe how genomic instability in cancer activates the cGAS-STING pathway through accumulation of cytoplasmic DNA. This results in the release of cytokines that attract lymphocytes into tumours. The cGAS-STING pathway is now known to be important in the response to novel cancer therapeutics that use the immune system to fight cancer such as PD-L1 inhibitors. The lab continue to investigate the mechanisms that activate the cGAS-STING pathway and how these can be harnessed to enhance the immune response to cancer.

Relevant publication:
https://pure.qub.ac.uk/portal/files/121087004/JNCI_J_Natl_Cancer_Inst_2017_Parkes_.pdf

Potential Projects

Although 20-30% of solid tumours overall have genomic instability and cGAS-STING activation that may sensitize them to immune checkpoint targeted therapies such as pembrolizumab or ipilimumab, the majority have minimal or no immune activation. We are therefore interested in identifying approaches to activating the cGAS-STING pathway in order to sensitize these tumours to immune checkpoint-targeted therapies. Recent publications in the virology field have suggested that STING may be regulated through the Ubiquitin-Proteasome system. We have therefore created a human E3 ligase and DUB siRNA library which can be used with a cGAS-STING pathway reporter cell line to identify novel drug targets to activate the pathway. Potential targets will fully characterised in further cell line models and the most promising will be taken forward into drug development in collaboration with Professor Tim Harrison (Medicinal Chemistry).